IPO registrations (S-1, F-1) · Registrants
Rain Oncology Inc.
- SEC CIK
- 1724979 · filings on EDGAR ↗
- Name on the registration
- Rain Therapeutics Inc.
- Former names
- Rain Therapeutics Inc. (2017–2022)
- Registration
- Form S-1, first filed 2021-04-02, last 2021-04-19; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2021-04-23; declared effective 2021-04-22
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 8000 JARVIS AVENUE, SUITE 204, Newark, CA 94560
- EIN
- 82-1130967
- EDGAR entity type
- operating
- Insiders and CEO pay
- Rain Oncology Inc. on the corporate pages
Offering terms
- Proposed price range
- $16.00–$18.00 per share (S-1/A filed 2021-04-19)
- Final price
- $17.00 per share, within the range (424B4 filed 2021-04-23, an initial public offering)
- Shares sold
- 7,352,941
- Gross proceeds
- $124,999,997 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol RAIN
- Lead underwriters
- Goldman Sachs (3,106,618 shares); Citigroup (2,261,029 shares); Piper Sandler (1,250,000 shares)
- Syndicate
- Guggenheim Securities (735,294)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: RAIN ONCOLOGY INC. EXACT (EIN (EXACT))
- Form D issuer: Rain Therapeutics Inc. EXACT (CIK (EXACT))
- SEC filer: Rain Oncology Inc. EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-04-02 | S-1 | S-1 (registration) | Rain Therapeutics Inc. | 0001193125-21-105078 ↗ |
| 2021-04-09 | S-1/A | S-1/A (amendment) | Rain Therapeutics Inc. | 0001193125-21-111673 ↗ |
| 2021-04-19 | S-1/A | S-1/A (amendment) | Rain Therapeutics Inc. | 0001193125-21-120267 ↗ |
| 2021-04-22 | EFFECT | EFFECT (declared effective) | Rain Therapeutics Inc. | 9999999995-21-001540 ↗ |
| 2021-04-23 | 424B4 | 424B4 (final prospectus) | Rain Therapeutics Inc. | 0001193125-21-129062 ↗ |
| 2022-06-06 | EFFECT | EFFECT (declared effective) | Rain Therapeutics Inc. | 9999999995-22-001705 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-04-19 | S-1/A | registration statement | $16.00–$18.00 | 7,352,941 | - | Nasdaq RAIN | 4 | primary document; range, price sentence, shares headline, proceeds computed, price outside the range dropped, cover names 4 | document ↗ | |
| 2021-04-23 | 424B4 | final prospectus | $17.00 | 7,352,941 | $124,999,997 | Nasdaq RAIN | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director | 9 | 2021–2024 | ||
| Boxer Asset Management Inc. | Other; TenPercentOwner | 3 | 2021–2023 | ||
| Boxer Capital, LLC | Director,Other; Director,TenPercentOwner | 3 | 2021–2023 | ||
| BRYCE RICHARD PAUL | Officer | Chief Medical Officer | 3 | 2021–2023 | |
| Cabatuan Nelson | Officer | See Remarks; VP of Finance & Admin | 4 | 2021–2023 | |
| Chen Bihua | Director; Director,TenPercentOwner | 2 | 2021 | ||
| Cormorant Asset Management, LP | Other; TenPercentOwner | 2 | 2021 | ||
| Cormorant Global Healthcare Master Fund, LP | Other; TenPercentOwner | 2 | 2021 | ||
| Cormorant Private Healthcare Fund III LP | Other; TenPercentOwner | 2 | 2021 | ||
| Cormorant Private Healthcare Fund II, LP | Other; TenPercentOwner | 2 | 2021 | ||
| Davis Aaron I. | Director; Director,TenPercentOwner | 7 | 2021–2024 | ||
| Doebele Robert | Officer | EVP, Chief Scientific Officer; See Remarks | 9 | 2021–2024 | |
| EDELMAN JOSEPH | TenPercentOwner | 3 | 2021 | ||
| Hrustanovic Gorjan | Director | 4 | 2021–2024 | ||
| LEWIS JOSEPH | Other; TenPercentOwner | 3 | 2021–2023 | ||
| MVA Investors, LLC | Director,TenPercentOwner | 2 | 2021 | ||
| Nguyen Tran | Director | 4 | 2021–2024 | ||
| PERCEPTIVE ADVISORS LLC | TenPercentOwner | 3 | 2021 | ||
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | TenPercentOwner | 3 | 2021 | ||
| Radovich Peter | Director | 5 | 2021–2024 | ||
| Vellanki Avanish | Director,Officer; Director,Officer,TenPercentOwner | Chairman and CEO; President and CEO | 9 | 2021–2024 | |
| Wolff Stefani | Director | 5 | 2021–2024 | ||
| BIOTECHNOLOGY VALUE FUND II LP | Director,Other; DirectorOther; Other | 12 | 2021–2024 | ||
| BIOTECHNOLOGY VALUE FUND L P | Director,Other; DirectorOther; Other | 12 | 2021–2024 | ||
| Biotechnology Value Trading Fund OS LP | Director,Other; DirectorOther; Other | 12 | 2021–2024 | ||
| BVF GP HOLDINGS LLC | Director,Other; Director,TenPercentOwnerOther; Other; TenPercentOwner | 12 | 2021–2024 | ||
| BVF I GP LLC | Director,Other; DirectorOther; Other | 12 | 2021–2024 | ||
| BVF II GP LLC | Director,Other; DirectorOther; Other | 12 | 2021–2024 | ||
| BVF INC/IL | Director,Other; Director,TenPercentOwnerOther; Other; TenPercentOwner | 12 | 2021–2024 | ||
| BVF PARTNERS L P/IL | Director,Other; DirectorOther; Director,TenPercentOwnerOther | 12 | 2021–2024 | ||
| BVF Partners OS Ltd. | Director,Other; DirectorOther; Other | 12 | 2021–2024 | ||
| LAMPERT MARK N | Director,Other; Director,TenPercentOwnerOther; Other; TenPercentOwner | 12 | 2021–2024 | ||
| Atkisson Erik | Officer | General Counsel and CCO | 4 | 2023–2024 | |
| TANG CAPITAL MANAGEMENT LLC | TenPercentOwner | 5 | 2023–2024 | ||
| TANG CAPITAL PARTNERS LP | TenPercentOwner | 5 | 2023–2024 | ||
| TANG KEVIN C | TenPercentOwner | 5 | 2023–2024 | ||
| Bruce Josephine | Officer | Principal Fin. & Acc. Officer | 2 | 2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-09-16 | Rain Therapeutics Inc. | Biotechnology | $72,601,590 | $72,601,555 | 18 | 1 |
| 2018-05-02 | Rain Therapeutics Inc. | Biotechnology | $18,363,604 | $18,363,604 | 8 | 1 |
| 2017-12-13 | Rain Therapeutics Inc. | Pharmaceuticals | $1,000,000 | $1,000,000 | 24 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | RAIN ONCOLOGY INC. | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Rain Therapeutics Inc. | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | Rain Oncology Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Rain Oncology Inc. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | RAIN ONCOLOGY INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.